Arcturus Therapeutics Holdings (ARCT) EBT (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly EBT came in at -$56.6 million in Q1 2026, down 302.2% YoY from $28.0 million in Q1 2025, and down 94.66% on a QoQ basis from -$29.1 million in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) EBT (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of EBT data on file, last reported at -$56.6 million in Q1 2026.
- Quarterly EBT fell 302.2% year-over-year to -$56.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.3 million (down 57.97% YoY) and the FY2025 annual result came in at -$65.8 million, up 18.73% from the prior year.
- EBT fell to -$56.6 million in Q1 2026, from -$29.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of $118.6 million in Q4 2022 to a low of -$56.6 million in Q1 2026.
- A 5-year average of -$13.0 million and a median of -$17.4 million in 2024 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT soared 413.74% — and 2026, when it slumped 302.2%.
- Tracing ARCT's EBT over 5 years: stood at $118.6 million in 2022, then tumbled by 109.65% to -$11.4 million in 2023, then sank by 162.2% to -$30.0 million in 2024, then grew by 3.09% to -$29.1 million in 2025, then plunged by 94.66% to -$56.6 million in 2026.
- The last three EBT figures came in at -$56.6 million (Q1 2026), -$29.1 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Arcturus Therapeutics Holdings | 233.92 Mn | 42.44 Mn | - | -23.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.79 Mn |
| Mar 31, 2026 | -56.61 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -7.12 Mn |
| Jun 30, 2024 | -17.37 Mn |
| Mar 31, 2024 | -26.45 Mn |
| Dec 31, 2023 | -11.45 Mn |
| Sep 30, 2023 | -15.33 Mn |
| Jun 30, 2023 | -51.97 Mn |
| Mar 31, 2023 | 50.86 Mn |
| Dec 31, 2022 | 118.64 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.17 Mn |
| Dec 31, 2021 | -37.82 Mn |
| Sep 30, 2021 | -61.28 Mn |